de en

Reagents and instruments for immunology, cell biology and molecular biology.

Semaglutide [910463-68-2]

Print

Cat# HY-114118-1mg

Size : 1mg

Contact local distributor :

Phone : +1 850 650 7790

Brand : MedChemExpress

Request more information

Contact local distributor :

Phone : +1 850 650 7790

Description	Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.
IC₅₀ & Target	GLP-1 receptor^[1].
In Vitro	Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib⁸, Arg³⁴) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM^[1]. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Semaglutide Related Antibodies
Solvent & Solubility	In Vitro: H₂O : 3.85 mg/mL (0.94 mM; ultrasonic and adjust pH to 1 with 1 M HCL) DMSO : < 1 mg/mL (insoluble or slightly soluble) Molarity Calculator Dilution Calculator Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass = Concentration × Volume × Molecular Weight * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) This equation is commonly abbreviated as: C₁V₁ = C₂V₂ Concentration _(start) C1 × Volume _(start) V1 = Concentration _(final) C2 × Volume _(final) V2 In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kg Animal weight (per animal) g Dosing volume (per animal) μL Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Calculation results: Working solution concentration: mg/mL The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE). Tel: 609-228-6898 E-mail: [email protected] Technical Support: [email protected]
Purity & Documentation	Purity: 99.84% Data Sheet (274 KB) SDS (419 KB) COA (248 KB) RP-HPLC (193 KB) Handling Instructions (2659 KB)
References	[1]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. [Content Brief] [2]. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80. [Content Brief] [3]. Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284. [Content Brief]

You might also be interested by the following products:

Cat#

Description

Cond.

Price Bef. VAT

T16728-1mg

Reldesemtiv [1345410-31-2]

1mg

T6650-1mg

Sabutoclax [1228108-65-3]

1mg